Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1600132/000160013218000157/a8-koctober2018actingcmo.htm
January 2023
January 2023
November 2022
September 2022
August 2022
June 2022
May 2022
March 2022
January 2022
January 2022
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1600132/000160013218000157/a8-koctober2018actingcmo.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Bellerophon Therapeutics, Inc..
Bellerophon Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Ticker: BLPHEvents:
CIK: 1600132
Form Type: 8-K Corporate News
Accession Number: 0001600132-18-000157
Submitted to the SEC: Wed Oct 24 2018 8:27:19 AM EST
Accepted by the SEC: Wed Oct 24 2018
Period: Wednesday, October 24, 2018
Industry: Pharmaceutical Preparations